Issue 2-84, 2018

Features of the Influence of Dynamic Stabilometry on the Degree of Severity of Chronic Fatigue Syndrome in Patients with Different Types of Multiple Sclerosis

View article (Download PDF file)



Download XML file

1,2,3 Shagaev A.S., 1 Boyko A.N., 2 Bakharev B.V.

1 Department of Neurology and Neurosurgery, Russian State Medical University, Moscow, Russia
2 Institute of Cell Biophysics RAS. City of Pushchino, Moscow region, Russia
3 Russian Academy of Sciences., Hospital №1 in Pushchino, Moscow region, Russia


ABSTRACT

Chronic fatigue (XY), along with motor and coordination disorders, is one of the most common syndromes in multiplesclerosis (MS). In spite of certain successes in the pathogenetic treatment of MS, the correction of the chronic fatiguesyndrome (CFS) remains completely unresolved. This report presents preliminary positive experience on the use of integratedreabilitation using the biofeedback method (BFB). The effectiveness of this method for the treatment of patientswith MS is shown. Recommendations are made about the possibility of using this method in patients with MS with varyingseverity of neurological deficit


KEYWORDS: multiple sclerosis, chronic fatigue stabilometric analysis, biological feedback, "center of pressure", symptomatic treatment, cytokines, moderate exercise, training, rehabilitation


References:

  1. Alekseeva T.G., Boiko A.N., Gusev E.I. [Range of neuropsychological changes at multiple sclerosis]. Zhurnal. nevrologii i psixixiatrii, Specialnyj vy-pusk. Rasseyannyj skleroz. Moscow,2000. Issue11. PP. 15-20.
  2. Alekseeva T.G.,Enikopolova E.V.,Sadal'skii E.V., i dr. [An integrated approach to assessment of cognitive and emotional and personal spheres at patients with multiple sclerosis]. Zhurnal nevrologii i psixiatrii. Specialnyj vypusk. Rasseyannyj skleroz. Moscow 2002. Issue1. PP. 20-26.
  3. Batysheva T.T. [The system of medical rehabilitation of motive violations at neurologic patients in out-patient conditions]. Avtoref.diss.na soiskanie uch.stepeni d.m.n. Moscow.2005. P. 64.
  4. Batysheva.T.T. [The system of medical rehabilitation of motive violations at neurologic patients in out-patient conditions]. Avtoref.diss.na soiskanie uch.stepeni d.m.n. Moscow.2005. P5.
  5. Baharev B.V. [Statistical data processing. Criteria of verification of data. Software package "statistics", materials on software of electronic comput-ers].Sb.trudov, g.Pushino.1989. Issue7. P. 34.
  6. Geht B.M., Merkulova.D.M., Kasatkina L.F., Samoilov.M.I. [Clinic, diagnostics and treatment of the polyneuropathies destroying a myelin]. Nevr. Zhurn. Moscow.1996. Issue1. PP. 12-17.
  7. Gusev E.I., Boiko.A.N.,Zavalishin.I.A. [Epidemiological researches of multiple sclerosis]. Metodicheskie rekomendacii. Moscow. 2003. № 2003/82. PP. 4-32.
  8. Gusev.E.I.,Boiko.A.N., Zavalishin. I.A. [Multiple sclerosis and destroying a myelin other diseases]. Ruk.dlja vrachei. Moscow: "Miklosh".2004. P. 8
  9. Demina M.L., Popova N.F. [Symptomatic therapy of multiple sclerosis]. J. Consilium Medicum. 2002.T.4; 2. PP. 6-9
  10. SHmidt T.E.,Elagina I.A., Jahno N.N. [Fatigue syndrome in various types of multiple sclerosis]. Nevr.Zhurn.2012.Issue3.PP. 12-19.
  11. Amato M.P ,Portaccio E. Management option in multiple sclerosis-assotiated fatigue. Expert OpinPharmacother. 2012; Vol.13.PP. 207-216: doi:10.1 517/14656566.2012.647767. [Pub Med].
  12. Berlestmann F.W, Polman C.H, VanDiemann HAM., et all, A comparison between 4-aminopyridine and 3,4-diaminopyridine in the treatment of multiple sclerosis. Ann Neurol 1992, Vol,32. P. 256.
  13. Bever CT., Panitch HS, Anderson PA, et al. The effects of 4-aminopyridine in multiple sclerosis patients : results of randomized, placebo-controled, double-blind , consentration-controlled, crossover trial. Neurology 1994, Vol.44. P. 1054-1059. doi.org.10.1212.WNL.44.6.1054
  14. Carro E, Nunez A, Busiguina S, Torres-Aleman I. Circulating insulin like growth factor I mediates effect of exercise on the brain. J. Neurosci. 2000. Vol20(8). P. 2926-2933.
  15. Carro E, Trijo JL, Busiguina S, Torres-Aleman I. Circulating insulin like growth factor I mediates the protective effects of physical exercise against brain insults of different etiology and anatomy. J.Neurosci. 2001. Vol. 21(15). P. 5678-5684.
  16. Castellano V, Patel D.I, White L I. Cytokine responses to acute and chronic exercise in multiple sclerosis . J. ApplPhisiol. 2008. Vol. 104. P. 1697-1702. Doi: 10.1152/ japplphysiol.00954.2007 [Pab. Med]
  17. Castellano, V. Patel, DI, White, LJ. Cytokine responses and PGC1 in inflammation and chronic disease. Nature. 2008. Vol.454 (24). P. 463-469.
  18. Flacheneker P, Bihler I. Cytocine mRNA ex-pression in patients with MS and fatigue.Mult.Scler. 2004. Vol.10.P. 165-169. Doi: 10.1191/1352458504ms 991oa. [Pab. Med].
  19. Gold SM, Kruger S, Ziegler KJ, Krieger T, Schulz KH, Otte C, Heesen C. Endocrine and Immune substrates of depressive symptoms and fatigue in multiple sclerosis patients with comorbid major depres-sion. J. NeurolNeurosurgPsychiatr. 2011. Vol 82. P. 814-818. Doi: 10.1136/jnnp.2010.2300.29. [Pub Med ].
  20. Golzari, Z, Shadkhis, F, Soudi, S, Kordi, MR, Hasmeri , SM. Combined exercise training redices IFN.-gamma and. IL-17 levels plasma and the suriph-eral blood mononuclear cells in women with multiple sclerosis. International Immunopharmacology. 2010. Vol. 10. P. 1415-1419.
  21. Gottschalk M. Kumpfel T, Flachenecker P, Uhr M, Trenkwalder C, Holsboer F, Weber F. Fatigue and regulation of the hypothalamo-pituitary-adrenal axis in multiple sclerosis . Arch Neurol. 2005. Vol.62. P. 277-280. Doi. 10.1001/archneur.62.2.277.[Pab. Med]
  22. Hessen C, Nawrath L, Reich N, Schulz KH, Gold SM. Fatigue in multiple sclerosis: an example of cytokine mediated sickness behaviour. J. Neurol-NeurosurgPsychitr. 2006. Vol.77. P. 34-39. Doi: 10.1136/jnnp. 2005.065805.[Pab Med].
  23. Hessen, C, Gold. SM, Hartmann, S, Mladek.,M, Reer, R, Braumann, KM, Wiedemann. K, Schulrz, KH. Endocrine and cytokine responses to standardized physical stress in multiple sclerosis. Brain. Behavior and Immunity. 2003. Val.17. P. 473-481.
  24. Kurtzke J.F. Rating neurological impairment in multiple sclerosis and expanded disability status scale (EDSS), Neurology. 1983. Vol. 33, P. 1444-52. PMID. 6685237
  25. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol .2001. Vol. 50. P. 121-127
  26. Schulz KN, Gold SM, Witte et al. Impact of aerobic training on immune-endocrine parameters, neurotrophic factors, quality of life and coordinative function in multiple sclerosis. J. Neurol Sci. 2004. Vol. 225(1-2). P. 11-18.
  27. The multiple sclerosis quality of life inventory: A User s Manual. National Multiple Sclerosis., 1999. P. 3.
  28. White, LJ, Castellano, V. McCoy. SC. Cytokine responses to resistansetraning in people with multiple sclerosis. Journal of Sports Scienes. 2006. Vol. 24(8). P. 911-914.
  29. Zwarts MJ, Bleijenberg G, van Engelen BG. Clinical neurophysiology of fatigue. Clinical neurophysiology. 2008. vol . 119. PP. 2-10.



Creative Commons License
The content is available under the Creative Commons Attribution 4.0 License.

©


This is an open article under the CC BY 4.0 license. Published by the National Medical Research Center for Rehabilitation and Balneology.